Cortexyme to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019
27 November 2019 - 8:05AM
Business Wire
-- Presentation to be webcast on Cortexyme’s
website --
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage
biopharmaceutical company pioneering a novel disease-modifying
therapeutic approach to treat what it believes to be a key
underlying cause of Alzheimer’s and other degenerative diseases,
today announced Casey Lynch, the company’s chief executive officer,
chair, and co-founder, will participate in a fireside chat at the
Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, December
3, 2019 at 2:00 p.m. EST / 11:00 a.m. PST in Boston.
A live webcast of the fireside chat will be accessible at the
Investor Calendar page under the News & Events heading of the
Cortexyme investor site (ir.cortexyme.com). The webcast will be
archived at that location for 90 days.
About Cortexyme, Inc.
Cortexyme (Nasdaq: CRTX) is a clinical stage biopharmaceutical
company pioneering a novel, disease-modifying therapeutic approach
to treat what it believes to be a key underlying cause of
Alzheimer’s disease and other degenerative diseases. Cortexyme is
targeting a specific, infectious pathogen found in the brain of
Alzheimer’s patients and tied to neurodegeneration and
neuroinflammation in animal models. The company’s lead
investigational medicine, COR388, is the subject of the GAIN Trial,
an ongoing Phase 2/3 clinical study in patients with mild to
moderate Alzheimer’s. To learn more about Cortexyme, visit
www.cortexyme.com or follow @Cortexyme on Twitter.
Forward-Looking Statements
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“expect,” “believe,” “will,” “may,” “should,” “estimate,”
“project,” “outlook,” “forecast” or other similar words.
Forward-looking statements are based on Cortexyme’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. Factors that could cause
actual results to differ include, but are not limited to, the risks
and uncertainties described in the section titled “Risk Factors” in
the final prospectus related to Cortexyme’s initial public offering
filed with the Securities and Exchange Commission on May 9, 2019
and Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on November 12, 2019. Forward-looking
statements contained in this press release are made as of this
date, and Cortexyme undertakes no duty to update such information
except as required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191126005817/en/
Hal Mackins For Cortexyme, Inc. hal@torchcomllc.com (415)
994-0040
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Apr 2024 to May 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From May 2023 to May 2024